ILLUMINA, INC. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Illumina, Inc. entered into a $1,000,000,000 revolving credit facility dated August 13, 2026, with Bank of America as administrative agent, JPMorgan Chase as syndication agent, and Citibank and Goldman Sachs as co-documentation agents. The facility matures August 13, 2031 (subject to extension), bears interest at Term SOFR or ABR plus applicable spreads (0.805%–1.300% depending on debt rating), and includes a $75 million letter-of-credit sublimit and $50 million swingline component. Pricing is tied to investment-grade ratings (Level III = BBB/Baa2); no financial covenants are stated in the excerpt, though a Total Net Leverage Ratio covenant is referenced in Section 6.04.
Why this rating
Routine debt refinancing/credit facility renewal. $1B commitment is ~11% of company's $9.2B market cap—material but standard for an established biotech. No unusual terms, counterparties, or size change relative to prior 2023 facility noted. Administrative action.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.